Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial.
Meredith M ReganOpeyemi A JagedeCharlene M MantiaThomas PowlesLillian WernerRobert J MotzerNizar M TannirChung-Han LeeYoshihiko TomitaMartin H VossElizabeth R PlimackToni K ChoueiriBrian I RiniHans J HammersBernard EscudierLaurence AlbigesStephen HuoViviana Del TejoBrian StwalleyMichael B AtkinsDavid F McDermottPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Patients initiating first-line nivolumab plus ipilimumab for aRCC spent more survival time treatment-free without toxicity versus those on sunitinib, regardless of risk group.